ストックスクリーナーアプリを入手
1.76
5.38%
-0.10
アフターアワーズ：
1.73
-0.03
-1.70%
前日終値:
$1.86
開ける：
$1.81
24時間の取引高:
110.15K
Relative Volume:
1.45
時価総額：
$264.92M
収益：
-
当期純損益:
-
株価収益率:
-7.8327
EPS:
-0.2247
ネットキャッシュフロー:
-
1週間 パフォーマンス:
-4.35%
1か月 パフォーマンス:
-8.81%
6か月 パフォーマンス:
-20.36%
1年 パフォーマンス:
-24.46%
1日の値動き範囲:
$1.76
$1.88
1週間の範囲:
$1.76
$1.94
52週間の値動き範囲:
$1.65
$3.335
Immutep Limited Adr Stock (IMMP) Company Profile
IMMP を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
IMMP
Immutep Limited Adr
|
1.76 | 264.92M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
484.82 | 131.41B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
634.23 | 72.26B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
591.87 | 36.10B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
270.02 | 35.03B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
272.17 | 28.24B | 3.81B | -644.79M | -669.77M | -6.24 |
Immutep Limited Adr Stock (IMMP) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2024-05-17 | 開始されました | CapitalOne | Overweight |
| 2023-08-03 | 開始されました | Robert W. Baird | Outperform |
| 2021-08-03 | 開始されました | Ladenburg Thalmann | Buy |
| 2021-07-16 | 再開されました | Maxim Group | Buy |
| 2018-09-28 | 開始されました | B. Riley FBR | Buy |
| 2018-02-15 | 繰り返されました | Maxim Group | Buy |
すべてを表示
Immutep Limited Adr (IMMP) 最新ニュース
Immutep Limited (ASX:IMM) Initiates Phase III Trial for Non-Small Cell Lung Cancer - thecapitalclub.com.au
LAG-3 Immunotherapies Market Set for Rapid Growth in the Coming 10 Years Across the 7MM as Next-Generation Therapies Advance | DelveInsight - GlobeNewswire Inc.
Immutep Limited (NASDAQ:IMMP) Shares Sold by Jane Street Group LLC - Defense World
Verition Fund Management LLC Has $57,000 Stock Position in Immutep Limited (NASDAQ:IMMP) - Defense World
Immutep Announces Initial Safety Data from First-in-Human Phase I Trial Evaluating IMP761 - The Manila Times
Immutep shares new cancer study results - Investing.com
Immutep Quarterly Activities Report Q1 FY25 - Yahoo Finance
Immutep Announces First-in-Human Phase I Study of IMP761 Progresses to Dose Escalation Portion of Trial - The Manila Times
Immutep reports positive results in cancer study - Investing.com
Immutep reports steady progress in Q4 FY24 By Investing.com - Investing.com Australia
Immutep Announces Successful Meeting with FDA on Phase III Design in Non-Small Cell Lung Cancer - GlobeNewswire
Immutep Receives Regulatory Clearance for Phase I Study of - GlobeNewswire
Baird cuts Immutep stock target on phase 2b trial results, retains Outperform - Investing.com
Immutep Appoints Leading Research Institute to Conduct First-in-Human Phase I Study of IMP761 - GlobeNewswire
10 Best Australian Stocks To Buy - Yahoo Finance
Immutep Announces Expansion of Triple Combination Therapy in 1st Line Non-Small Cell Lung Cancer - GlobeNewswire
Immutep Announces GMP Manufacturing Process Developed for - GlobeNewswire
Check Up: These 4 ASX healthcare stocks come with Strong Buy recommendations - Stockhead
ICE Announces Annual Reconstitution Changes in the ICE Biotechnology Index - Business Wire
FDA Grants Fast Track Designation to 1L Eftilagimod Alpha for Recurrent or Metastatic HNSCC - Targeted Oncology
Best Penny Stocks To Buy For 2021? 5 Biotech Stocks To Watch - Penny Stocks
IMMPImmutep Latest Stock News & Market Updates - StockTitan
The Daily Biotech Pulse: Moderna To Kickstart Phase 3 Study On July 27, Immutep Awarded Antibody Patent - Yahoo Finance
Benzinga's Daily Biotech Pulse: Organovo Falls On Earnings; Celgene Gets New CFO - Yahoo Finance
Immutep (IMMP) Stock Price, News & Analysis - MarketBeat
Immutep Limited Adr (IMMP) 財務データ
Immutep Limited Adr (IMMP) の財務データはありません。詳細については、他の銘柄を確認してください。
収益
当期純利益
現金流量
EPS
1.05%
1.79%
大文字化:
|
ボリューム (24 時間):